Edwards Lifesciences Corporation
EW
$75.15
-$0.74-0.98%
NYSE
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | 6.23% | 9.43% | 8.93% | 7.12% | 7.45% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 6.23% | 9.43% | 8.93% | 7.12% | 7.45% |
Cost of Revenue | 5.12% | 16.41% | 4.91% | 11.90% | 20.04% |
Gross Profit | 6.53% | 7.70% | 9.94% | 6.01% | 4.44% |
SG&A Expenses | 8.71% | 18.27% | 10.34% | 10.22% | 12.15% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | 87.10% | -- | -100.00% | -- |
Total Operating Expenses | 3.17% | 40.87% | 9.69% | -4.12% | 8.87% |
Operating Income | 14.53% | -33.71% | 7.12% | 54.89% | 3.77% |
Income Before Tax | 16.89% | 6.24% | 3.92% | 41.39% | 6.82% |
Income Tax Expenses | 51.84% | 32.26% | -22.77% | -2.96% | 2.21% |
Earnings from Continuing Operations | 11.91% | 3.57% | 8.12% | 45.00% | 7.51% |
Earnings from Discontinued Operations | -127.59% | 7.38% | 5,447.75% | -94.97% | -31.85% |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | 77.78% | 550.00% | 16.67% | -18.75% | -- |
Net Income | 1.73% | 4.24% | 697.82% | 19.28% | 3.35% |
EBIT | 14.53% | -33.71% | 7.12% | 54.89% | 3.77% |
EBITDA | 12.64% | -30.51% | 5.88% | 48.99% | 4.29% |
EPS Basic | 4.29% | 6.97% | 710.91% | 20.24% | 4.35% |
Normalized Basic EPS | 15.99% | -29.27% | 15.87% | 53.27% | 8.13% |
EPS Diluted | 4.22% | 7.08% | 716.06% | 19.57% | 5.52% |
Normalized Diluted EPS | 16.31% | -29.16% | 16.18% | 53.57% | 8.26% |
Average Basic Shares Outstanding | -2.44% | -2.54% | -1.61% | -0.79% | -0.97% |
Average Diluted Shares Outstanding | -2.70% | -2.70% | -1.87% | -0.98% | -1.11% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |